(Q37114840)

English

Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis

scientific article published on 18 March 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

18 August 2017

0 references

systematic review

1 reference

based on heuristic

inferred from title

1

object named as

Manju Mamtani

1 reference

Europe PubMed Central

18 August 2017

author name string

Hemant Kulkarni

2

1 reference

Europe PubMed Central

18 August 2017

language of work or name

0 references

publication date

18 March 2008

1 reference

Europe PubMed Central

18 August 2017

British Journal of Haematology

1 reference

Europe PubMed Central

18 August 2017

141

1 reference

Europe PubMed Central

18 August 2017

6

1 reference

Europe PubMed Central

18 August 2017

882-890

1 reference

Europe PubMed Central

18 August 2017

Cardiac status in well-treated patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Heart disease in thalassemia intermedia: a review of the underlying pathophysiology

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Heart failure in beta-thalassemia syndromes: a decade of progress

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Objectives and mechanism of iron chelation therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Heart failure in beta thalassemia: a 5-year follow-up study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Improved accuracy of low-power contrast echocardiography for the assessment of left ventricular remodeling compared with unenhanced harmonic echocardiography after acute myocardial infarction: comparison with cardiovascular magnetic resonance imagin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Light and shadows in the iron chelation treatment of haematological diseases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

The iron hypothesis:does iron play a role in atherosclerosis?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Deferiprone: New insight.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

R2* imaging of transfusional iron burden at 3T and comparison with 1.5T.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

The thalassaemias

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Tricuspid regurgitation in patients with beta-thalassemia major

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07122.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2008.07122.X

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37114840&oldid=1741669945"